(Press-News.org) SAN FRANCISCO (March 10, 2013) — A clot-busting therapy may benefit some heart attack patients who cannot have immediate angioplasty, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
"Drug therapy before transfer is at least as effective as [angioplasty], and an urgent catheterization was avoided in two-thirds of patients," said Frans Van de Werf, MD, PhD, professor of cardiology at University of Leuven, Belgium, and the study's lead investigator.
"It gives [clinicians] time to consider other options, such as [coronary artery bypass graft] and medical therapy."
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) trial included 1,915 patients from 15 countries. All had ST-elevation myocardial infarction (STEMI), a type of heart attack caused by a blood clot completely blocking one of the heart's arteries. Patients were first seen in community hospitals or by emergency medical personnel. In these settings, immediate angioplasty—the preferred first-line treatment for STEMI—was not possible until patients were transferred to a major medical center.
Before transfer, subjects were randomized to either angioplasty—also called PCI, or percutaneous coronary intervention—immediately after arrival or to drug therapy with tenecteplase plus enoxaparine, clopidogrel and aspirin before arrival. When patients on tenecteplase reached a medical center, about one-third needed urgent angioplasty. The other two-thirds did not. They received an angiogram an average of 17 hours after arrival. Based on the results of the angiogram, patients received either PCI or coronary artery bypass graft surgery under non-urgent circumstances.
The primary endpoint was a composite of all-cause mortality, shock, congestive heart failure and subsequent heart attack within 30 days. Results were similar between the immediate PCI group and the tenecteplase group (14.3 vs. 12.4 percent, p=0.211). There were no differences in cardiac-specific mortality or cardiac rehospitalization.
Patients receiving tenecteplase were more likely to have normal blood flow on an angiogram, compared with the PCI-only group (58 vs. 21 percent). They were less likely than the PCI-only group to have an angiogram show complete blockage of an artery (16 vs. 59 percent). More tenecteplase patients than PCI-only patients eventually underwent coronary artery bypass graft surgery.
During the course of the trial, researchers halved the dose of tenecteplase in people ages 75 and older to minimize cranial bleeding, a common complication of clot-busting therapy. The incidence of such bleeding in the total study population was 0.5 percent after the dose reduction.
"We offer this pharmaceutical strategy with timely coronary angiography as an alternative to primary PCI," Dr. Van de Werf said. "We believe that it may be helpful in some early-presenting patients for whom immediate PCI is not possible."
### The study was funded by Boehringer Ingelheim. Dr. Van de Werf's institution, the University of Leuven, received a grant from Boehringer Ingelheim to conduct the STREAM trial, as well as funding for a study of dabigatran in patients with a mechanical heart valve.
The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC13 for the latest news from the meeting.
The American College of Cardiology is a nonprofit medical society comprised of 43,000 physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is dedicated to transforming cardiovascular care, improving heart health and advancing quality improvement, patient-centered care, payment innovation and professionalism. The ACC also leads the formulation of important cardiovascular health policy, standards and guidelines. It bestows credentials upon cardiovascular specialists, provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality care. For more information, visit cardiosource.org.
This study will be simultaneously published online in the New England Journal of Medicine at the time of presentation.
Dr. Van de Werf will be available to the media on Sunday, March 10, at 12:30 p.m., in Moscone Center, South, Room 300.
Dr. Van de Werf will present "The STREAM Trial" on Sunday, March 10, at 10:45 a.m., in Moscone Center, South, Esplanade Ballroom.
Media Contacts
Beth Casteel
240-328-4549
bcasteel@acc.org
Nick Mitsis
703-951-3589
acc@ecius.net
ACC.13 News Room
415-978-3511
Clot-busting drug as effective as angioplasty
STREAM trial: Treatment with tenecteplase before hospital transfer benefits some
2013-03-12
ELSE PRESS RELEASES FROM THIS DATE:
Drug reduces chest pain in patients with diabetes
2013-03-12
SAN FRANCISCO (March 10, 2013) — A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Ranolazine is approved by the U.S. Food and Drug Administration for the treatment of chronic angina, or chest pain, both as first line therapy and as an add-on when symptoms are not relieved with other anti-anginal drugs, including beta-blockers, calcium channel ...
High-dose oral vitamins, minerals do not reduce recurrent cardiac events in heart attack patients
2013-03-12
SAN FRANCISCO (March 10, 2013) — Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. However, the results of one component of the NIH-funded Trial to Assess Chelation Therapy (TACT) study, shows that when combined with active chelation therapy, high-dose vitamins and minerals may provide some additional benefit.
The TACT study tested the safety and effectiveness of ...
Digoxin reduces hospital admissions in older patients with chronic heart failure
2013-03-12
SAN FRANCISCO (March 11, 2013) —Digoxin significantly reduces the likelihood of hospital admission due to all causes among ambulatory older patients with chronic heart failure and reduced ejection fraction (HFrEF), according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Researchers reviewed patient outcomes from 1995 in the Digitalis Investigation Group (DIG) trial of 6,800 patients with HFrEF—a condition in which the heart is too weak to pump and patients suffer from breathlessness and fatigue. Patients with HFrEF ...
Clot-busting drug benefits intermediate-risk patients with pulmonary embolism
2013-03-12
SAN FRANCISCO (March 11, 2013) — The clot-busting drug tenecteplase prevents death or circulatory collapse in a subgroup of patients with a blood clot in the lungs and appears to be especially useful in patients younger than 75, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Pulmonary embolism occurs when part of a blood clot in a vein breaks off and travels to the lungs. It is fatal about 10 percent of the time, killing between 60,000 and 100,000 Americans each year. The most common cause of death is progressive ...
Screenings, targeted care reduce heart failure in at-risk patients
2013-03-12
SAN FRANCISCO (March 11, 2013) — For at-risk patients, a simple screening and management program can be effective in preventing heart failure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
The five-year STOP-HF study enrolled asymptomatic patients over 40 years of age with risk factors for heart failure and randomized them into an intervention and a control group. Patients in the intervention group were screened for blood levels of B-type natriuretic peptide (BNP), a hormone that indicates how well the heart ...
No benefit found from BP drug in treatment of recently hospitalized heart failure patients
2013-03-12
SAN FRANCISCO (March 11, 2013) —Despite high hopes that a blood pressure-lowering medication called aliskiren would help people following hospitalization for heart failure, no beneficial effects were found, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Heart failure is the leading cause of hospitalization for people over age 65, costing Medicare billions of dollars annually, and researchers are always on the lookout for more effective treatments.
The Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) ...
Erectile dysfunction drug fails for diastolic heart failure patients
2013-03-12
SAN FRANCISCO (March 11, 2013) — Despite high expectations for a commonly used erectile dysfunction drug to treat patients with diastolic heart failure, no beneficial effects were found in a study presented today at the American College of Cardiology's 62nd Annual Scientific Session.
The RELAX Study is the first multicenter trial to look at the effect of chronic therapy with sildenafil in diastolic heart failure. Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor, a class of drugs used to treat erectile dysfunction and certain types of pulmonary arterial hypertension. ...
Low T3 syndrome predicts unfavorable outcomes in surgical patients with brain tumor
2013-03-12
Charlottesville, VA (March 12, 2013). In a study of 90 patients undergoing surgery for brain tumor, researchers in Lithuania (Lithuanian University of Health Sciences) and the United States (University of North Carolina at Chapel Hill and Brigham & Women's Hospital, Harvard University) have discovered that the finding of low T3 (triiodothyronine) syndrome is predictive of unfavorable clinical outcomes and depressive symptoms. Details of this study are furnished in the article "Low triiodothyronine syndrome as a predictor of poor outcomes in patients undergoing brain tumor ...
What impact does a day of roller derby have on our skin microbiome?
2013-03-12
The human skin is home to countless microorganisms that we can't see, but these microbes help define who we are. Our invisible passengers – known as the skin microbiome - contribute to our health in numerous ways including educating our immune system, protecting us from pathogens, and mediating skin disorders. In a new study, researchers investigated how the skin microbiome is transmitted between players in a contact sport, using roller derby as their model system.
The skin is the largest organ and an important barrier that regulates microbial entry into the human body. ...
Hereditary neurodegeneration linked to ADP-ribose modification
2013-03-12
HEIDELBERG, 12 March 2013 – Attaching chains of the small molecule ADP-ribose to proteins is important for a cell's survival and the repair of DNA damage, making this process a promising target for the development of new cancer drugs. Researchers have now identified a much sought after enzyme that removes such ADP-ribose modifications from proteins by studying a genetic mutation that causes neurodegenerative disease in humans. These findings, published today in The EMBO Journal, suggest that not only addition but also removal of ADP-ribose from proteins is essential for ...
LAST 30 PRESS RELEASES:
Thirty-year mystery of dissonance in the “ringing” of black holes explained
Less intensive works best for agricultural soil
Arctic rivers project receives “national champion” designation from frontiers foundation
Computational biology paves the way for new ALS tests
Study offers new hope for babies born with opioid withdrawal syndrome
UT, Volkswagen Group of America celebrate research partnership
New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll
Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes
University of Cincinnati Cancer Center presents research at AACR 2025
Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025
AACR: Researchers share promising results from MD Anderson clinical trials
New research explains why our waistlines expand in middle age
Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker
Chips off the old block
Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia
Cutting the complexity from digital carpentry
Lung immune cell type “quietly” controls inflammation in COVID-19
Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity
State and sociodemographic trends in US cigarette smoking with future projections
Young adults drive historic decline in smoking
NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research
Chimpanzee stem cells offer new insights into early embryonic development
This injected protein-like polymer helps tissues heal after a heart attack
FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology
In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity
Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects
A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions
AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate
Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative
Structure dictates effectiveness, safety in nanomedicine
[Press-News.org] Clot-busting drug as effective as angioplastySTREAM trial: Treatment with tenecteplase before hospital transfer benefits some